

AD_____

AWARD NUMBER: W81XWH-13-1-0032

TITLE: Tumor Genomic Profiling in Breast Cancer Patients Using Targeted Massively Parallel Sequencing

PRINCIPAL INVESTIGATOR: Nikhil Wagle

RECIPIENT: Dana-Farber Cancer Institute
Boston MA 02115

REPORT DATE: January 2014

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE January 2014		2. REPORT TYPE Annual		3. DATES COVERED 01 January 2013 - 31 December 2013	
4. TITLE AND SUBTITLE Tumor genomic profiling in breast cancer patients using targeted massively parallel sequencing				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-13-1-0032	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Nikhil Wagle E-Mail: nwagle@partners.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Dana-Farber Cancer Institute Boston MA 02115				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The overarching goal of this proposal is to use massively parallel sequencing to detect somatic genomic alterations in breast cancer tumor samples in order to identify genetic determinants of tumor behavior that may inform clinical decision-making. To date, we have developed a targeted sequencing platform that interrogates ~450 genes that are known to be altered in breast cancer and other cancers. We now plan to utilize this platform to study 150 tumor samples from women with ER+ breast cancer who have had early-, late- or no relapse following endocrine therapy. We have also begun to sequence tumor samples from patients with advanced breast cancer. To date, we have performed whole exome sequencing on 8 patients. In 4 patients, we identified somatic genomic alterations with potential clinical impact. In 5 of the 8 patients, we also obtained and sequenced tumor samples at the time of resistance to targeted therapies. In some cases, known mechanisms of resistance (i.e., ligand-binding domain mutations in ESR1) were identified. Analysis is currently underway to further elucidate causes of resistance in those cases where the mechanism is unclear.					
15. SUBJECT TERMS Breast Cancer, Genomics, Resistance, Sequencing, Exome, Recurrence					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 17	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Overall Project Summary	4
4. Key Research Accomplishments	9
5. Conclusion	9
6. Publications, Abstracts, and Presentations	9
7. Inventions, Patents and Licenses	14
8. Reportable Outcomes	14
9. Other Achievements	14
10. Training and Professional Development	16
11. References	16

1. INTRODUCTION:

Knowledge of genetic changes that occur in cancer cells should ultimately facilitate individualized approaches to cancer treatment. However, methods to systematically profile cancers for relevant genetic changes in the clinical setting remain underdeveloped. The overarching goal of this proposal is to use cutting-edge genomic technology (massively parallel sequencing) in patients with breast cancer to identify genetic determinants of tumor behavior that may inform clinical decision-making. Two unmet clinical challenges in breast cancer motivate this approach. The first is the need for improved biological understanding of early stage estrogen-receptor positive (ER+) tumors with a high risk of recurrence. Systematic genetic profiling of early stage ER+ tumors may identify specific subsets of breast cancer and predict which patients are most likely to relapse. Second, there is a clear need for novel therapeutic strategies in metastatic breast cancers that have become resistant to standard therapies. Systematic genetic characterization of these resistant cancers might teach us about new therapeutic strategies or guide the development of targeted drug combinations that may help to overcome cancer drug resistance. Thus, in this study, we aim to profile a clinically annotated cohort of 150 ER+ breast tumors to look for genetic differences in both early-recurring and late-recurring tumors. In addition, we aim to prospectively profile 50 patients with advanced breast cancer in order to study the impact of our approach in a setting that may ultimately inform clinical decision-making.

2. KEYWORDS:

Breast Cancer
Estrogen Receptor
Resistance
Recurrence
Massively Parallel Sequencing
Next Generation Sequencing
Targeted Sequencing
Whole Exome Sequencing
Genomics
Personalized Medicine
Precision Medicine

3. OVERALL PROJECT SUMMARY:

AIM #1: To perform genomic profiling across a clinically annotated cohort of ER+ breast tumors

The goal of this Aim is to establish a breast-cancer focused mutation profiling platform and use it to study an annotated collection of tumor samples from patients with ER+ breast cancers. To date, we have completed the design and construction of this targeted sequencing platform that can be used on FFPE tumor samples. This platform targets all known breast cancer related genes identified in large sequencing studies of breast cancer samples from the past 2 years. We have also recently developed an updated version of this platform (v2.0), including several novel genomic alterations that we and others have recently identified in ER+ breast cancer samples. Sample collection and sequencing has been not yet started on this cohort due to unforeseen

technical issues with the implementation of the targeted sequencing platform. Now that the platform is operational, sequencing is expected to begin shortly.

AIM 1A: To develop a breast cancer-focused massively parallel sequencing platform for FFPE samples

4 large sequencing studies (published in *Nature* in 2012) used whole exome and/or whole genome sequencing to catalogue the landscape of genomic alterations in primary, treatment-naïve breast cancers¹⁻⁴. In total, 819 primary breast cancers were sequenced across these 4 studies, of which 529 were

Study	Total Number of Breast Tumors	Total Number of ER+ Tumors
Stephens et al ¹	100 primary tumors	79 ER+ primary tumors
Banerji et al ²	108 primary tumors	60 ER+ primary tumors
Shah et al ³	104 primary tumors (triple negative)	0 ER+ primary tumors
TCGA ⁴	507 primary tumors	390 ER+ primary tumors
TOTAL	819 primary tumors	529 ER+ primary tumors

Table 1: Large-scale sequencing studies in breast cancer

ER+ (**Table 1**). A fifth study by Matthew Ellis and colleague⁵ reported the sequencing of 77 pretreatment tumor biopsies (46 whole genomes and 31 whole exomes) from patients with luminal breast cancer treated with a neoadjuvant aromatase inhibitor. This study was designed to identify genomic biomarkers that may predict response or intrinsic (*de novo*) resistance to endocrine therapy. Based on Ki67 levels in the surgical specimens, samples were stratified into AI-sensitive (Ki67 < 10%, n = 48) and AI-resistant samples (Ki67 > 10%, n = 29). Mutations in *MAP3K1* and possibly *GATA3* were associated with AI-sensitivity, while *TP53* mutations were associated with the AI-resistance. In the aggregate, these five studies have shed tremendous light onto the genomics of primary treatment-naïve breast tumors.

As described in our original research proposal, we developed an enriched set of genes including these new significantly altered genes identified in breast cancer, as well as numerous other novel cancer genes that have recently been identified. **In total, this design included all of the exons from 435 genes, selected introns to identify translocations from 22 genes, more extensive tiling across the entirety of 23 genes, and the promoter of the TERT gene.** The resultant list of genomic coordinates were optimized and a set of baits were designed and synthesized. Implementation of the new baits into the targeted sequencing platform was delayed due to several unforeseen technical issues. However, these issues were resolved and we have recently completed testing and implementation of this platform, as described in our original research proposal.

More recently, we have identified several novel alterations in in ER+ breast tumors, including translocations in *ESR1*, the gene that encodes the estrogen receptor (Wagle, Garraway, and Arteaga, unpublished results). Given the potential importance of ESR translocations in ER+ breast cancer, we have further modified our bait design to include genomic coordinates across select introns in ESR1. In addition, two recent papers from the Broad Institute published in *Nature* in 2013 highlighted several novel cancer genes not previously identified as significant in cancer^{6,7}. All of these alterations were also added to our targeted sequencing panel design, and a 2nd iteration (v2.0) is now under development. We expected to test this version over the next several months, and if successful it may replace v1.0.

TASKS:

- Design and optimization of breast-cancer specific platform (Month 1 – Month 4):
COMPLETE

AIM 1B: To perform genomic profiling across a clinically annotated cohort of ER+ breast tumors

In this aim, we proposed to use our breast-cancer focused platform to profile a cohort of early stage ER+ breast tumors that have recurred after adjuvant therapy. Due to delays in the implementation of the sequencing platform outlined above, the collection and sequencing of these samples has not yet begun. Sample collection is now expected to be completed by month 15. However, due to significant process improvements and increased efficiency, the time for DNA extraction, library construction, hybrid selection, and targeted sequencing has been reduced since the time of grant application. Therefore, we now expect the entire cohort of 150 samples to have completed sequencing within 3 months total of sample collection (month 18). Analysis and validation will be completed by month 24, and statistical analysis should be completed by month 27, a total delay of 9 months.

TASKS (WITH REVISED TIMELINE):

- Sample collection (Month 12 – Month 15)
- DNA extraction, quantitation, and library construction (Month 16)
- Targeted massively parallel sequencing (Month 17 – Month 18)
- Analysis of sequencing data (Month 19 – Month 21)
- Validation of alterations (Month 21 – Month 24)
- Statistical analysis (Month 21 – Month 27)

REVISED MILESTONES:

- All samples collected by *Month 15*
- All sequencing completed by *Month 18*
- Statistical analysis completed by *Month 24*

AIM #2: To assess the feasibility of prospective sequencing in patients with advanced breast cancer

In this Aim, we proposed to apply our sequencing platform to patients with advanced breast cancer. The goal here is to study the feasibility of our approach in a setting that may ultimately inform clinical decision-making. This will serve as a proof-of-principle for how this platform could be used prospectively to uncover somatic genetic changes that impact the treatment and prognosis of patients with breast cancer. Because of the delay in implementing the new targeted sequencing platform, our focus here has been on performing *whole exome sequencing* in patients with advanced breast cancer.

We recently established a pipeline for **prospective whole exome sequencing** from FFPE tumor samples to support clinical decision making (and clinical trial enrollment) for appropriately consented patients with advanced cancers at the Dana-Farber Cancer Institute (DFCI) known as **CanSeq**. We conducted a pilot study on 16 patients that has enabled optimization of various aspects of our emerging clinical sequencing pipeline, including sample acquisition, DNA

extraction, sequencing, and analysis. The somatic and germline alterations were analyzed using a newly-developed heuristic algorithm that we presented at the 2012 ASCO Annual Meeting (Van Allen, Wagle, et al). This algorithm applies a categorization framework that incorporates the degree of actionability and level of evidence for that action. A similar algorithm has also been developed for germline alterations. We have also developed a customized report that streamlines the results of these algorithms for presentation to our Cancer Genomics Evaluation Committee, a multi-disciplinary “genomics tumor board” which makes decisions about the interpretation and clinical actionability of somatic and germline alterations. Somatic analysis of the first 16 patients demonstrated at least one plausibly actionable somatic alteration linked to an approved or experimental therapy in 15 out of 16 cases. This work was presented in two posters at the 2013 AACR Annual Meeting (Wagle N, Van Allen E, et al, 2013 AACR Annual Meeting; Van Allen EM, Wagle N, et al., 2013 AACR Annual Meeting). Our manuscript describing this approach and the pilot study is currently *in press* in Nature Medicine (Van Allen, Wagle, et al, 2014).

AIM 2A: To assess the clinical impact of prospective genomic profiling in advanced breast cancer

Using this CanSeq pipeline, we have begun to sequencing patients with advanced breast cancer in order to identify genomic alterations that may aid with clinical decision making. To date, we have performed whole-exome sequencing on tumor samples from 8 patients with advanced breast cancer. The relevant genomic findings are summarized in **Table 2**:

Patient	Clinically Relevant Somatic Alterations Identified	Associated Clinical Actions	Clinical Actions Taken Due to Sequencing Results
Patient 1	PIK3CA activating mutation	PI3-kinase inhibitor	None (patient is deceased)
Patient 2	CDKN1B loss-of-function mutation	CDK inhibitor	CDK4/6 inhibitor trial enrollment
Patient 3	None		
Patient 4	FGFR1 amplification	FGFR inhibitor	None to date
Patient 5	None		
Patient 6	JAK2 mutation	JAK2 inhibitor	None to date
Patient 7	PIK3CA activating mutation	PI3-kinase inhibitor	PI3-kinase inhibitor trial (mutation was already known)
Patient 8	<in analysis>		

TABLE 2

Enrollment, sequencing, analysis, interpretation, and reporting to physicians and patients continue. An interim analysis of feasibility and clinical impact is planned when enrollment reaches 10 patients, as described in the original proposal.

TASKS:

- Protocol activation (Month 1 – Month 3):
COMPLETE
- Patient enrollment (Month 4 – Month 36):
IN PROGRESS

- Sample acquisition (Month 4 – Month 36):
IN PROGRESS
- Genomic profiling (including DNA extraction, library construction, sequencing, and validation) (Month 4 – Month 36):
IN PROGRESS
- Interpretation of genomic alterations and reporting to physicians/patients (Month 4 – Month 36):
IN PROGRESS
- Analysis of feasibility and clinical impact (Month 4 – Month 36):
IN PROGRESS

MILESTONES:

- Protocol activated and patient enrollment begins by *Month 4*:
COMPLETE
- Sequencing of first 5-10 patients completed and reported to physician/patient by *Month 9*:
8 PATIENTS COMPLETE
- Analysis of feasibility and clinical impact of first 5-10 patients by *Month 12*:
IN PROGRESS
- Sequencing of first 20 patients completed and reported to physician/patient by *Month 18*
- Analysis of feasibility and clinical impact of first 20 patients by *Month 21*
- Sequencing of at least 50 patients completed and reported to physician/patient by *Month 33*
- Analysis of feasibility and clinical impact of 50 patients by *Month 36*

AIM 2B: To use whole-exome sequencing to identify genomic mechanisms of therapeutic resistance

The goal of this aim is perform whole exome sequencing in breast cancer patients who develop resistance to targeted therapies (e.g., endocrine therapies, anti-Her2 therapies, PI3K inhibitors, mTOR inhibitors) in order to identify novel resistance mechanisms. These patients will be re-consented for repeat metastatic biopsy and the new samples profiled to determine alterations that may have led to therapeutic resistance.

Of the 8 enrolled patients described above, 5 patients were profiled at the time of resistance to a targeted therapy, as shown in **Table 3**:

Patient	Agent to Which Resistance Was Acquired	Candidate Resistance Mutation Identified in Resistance Tumor	Detectable in Pretreatment Tumor?
Patient 1	Endocrine Therapy	ESR1 resistance mutation	No
Patient 2	Endocrine Therapy	ESR1 resistance mutation	Sample Unavailable
Patient 3	Endocrine Therapy	ESR1 resistance mutation	<SAMPLE PENDING>
Patient 6	MET Inhibitor	Unknown at present	<SAMPLE PENDING>
Patient 7	PI3Kalpha inhibitor	Unknown at present	Unknown at present

Patient 8	Endocrine Therapy	<in analysis>	<SAMPLE PENDING>
-----------	-------------------	---------------	------------------

TABLE 3

We are in the process of obtaining and sequencing the pretreatment samples from several of these patients, as indicated. A comparative analysis of the paired pre-treatment and post-resistance samples will continue as we obtain additional samples. We will continue to obtain pre-treatment and resistant samples from additional patients as they become available.

TASKS:

- Whole exome sequencing of patients with acquired resistance to targeted therapies (Month 9 – Month 36): IN PROGRESS

MILESTONES:

- Whole exome sequencing on first 3-6 patients with acquired resistance completed by ***Month 16: 3 PATIENTS COMPLETE***
- Whole exome sequencing of at least 15 patients with acquired resistance completed by ***Month 33***

4. KEY RESEARCH ACCOMPLISHMENTS:

- Development of a novel targeted sequencing platform that includes ~450 genes (v1.0) that are significantly altered in breast cancer and other cancers, including novel unpublished alterations that we have recently identified in ER+ breast cancers
- Development of a prospective whole exome sequencing pipeline (CanSeq) that includes sequencing from FFPE samples, analysis, curation, and interpretation of clinically relevant somatic and germline alterations, discussion of key findings by the Cancer Genome Evaluation Committee, and return of results to physicians and patient (Van Allen, Wagle, et al, Nature Medicine, In Press)

5. CONCLUSION:

To date, we have made significant progress on this research project. Given the progress to date, we anticipate that we will achieve our stated research goals by the end of the grant term. To accomplish this, we will utilize the targeted sequencing panel we have developed to profile 150 early stage ER+ breast cancers, as we have described. We will continue to perform whole exome and targeted sequencing on patients with advanced breast cancer until we reach our stated goal of 50 patients. For the subset of patients who develop resistance to therapies, we will perform additional sequencing to compare their resistant tumor to their pre-treatment sensitive tumor, as we have demonstrated for several patients already.

Once successfully completed, this work should provide new knowledge that informs the development of novel treatment strategies in breast cancer. These include treatments that may prevent early and/or late recurrence in ER+ breast cancers, new approaches to determining how best to use targeted therapies in advanced breast cancer, and novel strategies to overcome resistance mechanisms. If widely deployed, implementation of this approach may open new opportunities to link cancer genomics with molecular features, clinical outcomes, and

treatment response in patients with breast cancer. This approach may ultimately impact clinical practice by offering a categorical means to identify genetic changes affecting genes and pathways targeted by existing and emerging drugs, thereby speeding the advent of personalized cancer medicine.

6. PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

a. Manuscripts:

(1) Lay Press:

None

(2) Peer-Reviewed Scientific Journals:

1. Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba M, Meszoley IM, **Wagle N**, Garraway LA, and Arteaga CL. Discordant cellular response to pre-surgical letrozole in bilateral synchronous ER+ breast with a KRAS mutation or FGFR1 gene amplification. *Molecular Cancer Therapeutics*. 2012 Oct;11(10):2301-5. Epub 2012 Aug 9.
2. Whittaker SR, Theurillat JP, Van Allen E, **Wagle N**, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. *Cancer Discovery*. 2013 Mar;3(3):350-62. Epub 2013 Jan 3.
3. Lane AA, Odejide O, Kopp N, Kim S, Yoda A, Erlich R, **Wagle N**, Abel GA, Rodig SJ, Antin JH, Weinstock DM. Low frequency clonal mutations recoverable by deep sequencing in Patients with aplastic anemia. *Leukemia*. 2013 Apr;27(4):968-71. Epub 2013 Feb 1.
4. Vaz-Luis I, Seah D, Olson EM, **Wagle N**, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. *Clin Breast Cancer*. 2013 Aug;13(4):254-63.
5. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, Macconail LE, Shoni M, **Wagle N**, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS. Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. *Cancer*. 2013 Nov 1;119(21):3776-83. Epub 2013 Aug 23.
6. Berg JS, Amendola LM, Eng C, Allen EV, Gray SW, **Wagle N**, Rehm HL, Dechene ET, Dulik MC, Hisama FM, Burke W, Spinner NB, Garraway L, Green RC, Plon S, Evans JP, Jarvik GP. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. *Genet Med*. 2013 Nov;15(11):860-7. Epub 2013 Oct 24.
7. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, **Wagle N**, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. *Invest New Drugs*. 2013 Nov 16. [Epub ahead of print]
8. Van Allen EM*, **Wagle N***, Sucker A, Treacy D, Johannessen C, Goetz EM, Place CS,

Taylor-Weiner A, Whittaker S, Kryukov G, Hodis E, Rosenberg M, Cibulskis K, Farlow DN, Zimmer L, Hillen U, Gutzmer R, Goldinger S, Ugurel S, Gogas H, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel S, Carter SL, Getz G, Garraway LA, and Schadendorf D. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. *Cancer Discovery*. 2014 Jan;4(1):94-109. Epub 2013 Nov 21.

(*Dual-First Author)

9. **Wagle N***, Van Allen EM*, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty K, Wargo JA, and Garraway LA. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. *Cancer Discovery*. 2014 Jan;4(1):61-8. Epub 2013 Nov 21.
 10. Van Allen EM, Foye A, **Wagle N**, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. *Prostate Cancer Prostatic Dis*. 2013 Dec 24 [Epub ahead of print].
 11. Van Allen EM*, **Wagle N***, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Kiezun A, Voet D, Lawrence M, Lichtenstein LT, Gentry JG, Huang FW, Farlow D, Barbie D, Gandhi L, Lander ES, Gray SW, Joffe S, Janne P, Garber J, MacConaill L, Lindeman N, Rollins B, Kantoff P, Fisher SA, Gabriel S, Getz G, and Garraway LA. Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine. *Nature Medicine (In Press)*.
- (*Dual-First Author)
12. **Wagle N**, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko J, Stewart M, Choueiri TK, Gandhi L, Cleary J, Elfiky A, Taplin ME, Stack EC, Loda M, Shapiro G, Shamji A, Schreiber S, Sabatini D, Kantoff P, Garraway LA, and Rosenberg J. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. *Cancer Discovery (In Press)*.

(3) Invited Articles:

1. Van Allen E, **Wagle N**, and Levy MA. The clinical analysis and interpretation of cancer genome data. *Journal of Clinical Oncology*. 2013 May 20;31(15):1825-33. Epub 2013 Apr 15.

(4) Abstracts:

1. Vaz-Luis I, Seah D, Olson E, Metzger O, **Wagle N**, Sohl J, Litsas G, Burstein H, Krop I, Winer E, and Lin NU. Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy. 2012 San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2012.
2. **Wagle N**, Van Allen E, Perrin D, Friedrich D, Fisher S, Kryukov G, Ambrogio L, Auclair D, Gray S, Joffe S, Janne P, Garber J, Macconail L, Lindeman N, Rollins B, Kantoff P, Getz G, Gabriel S, and Garraway LA. CanSeq: prospective clinical whole-exome sequencing of

FFPE tumor samples. 104th American Association for Cancer Research Annual Meeting, Washington, DC, April 6-10, 2013.

3. Van Allen EM, **Wagle N**, Keizun A, Kryukov G, McKenna A, Huang F, Hiller E, Rainville I, Auclair D, Ambrogio L, Gray S, Joffe S, Getz G, Garber J, and Garraway L. An integrated germline analysis platform for comprehensive clinical cancer genomics. 104th American Association for Cancer Research Annual Meeting, Washington, DC, April 6-10, 2013.
4. Van Hummelen P, Ducar M, Jones RT, Raza A, Sunkavalli A, Hanna M, Mills A, Adusumilli R, Kumar P, Schubert L, Breneiser M, Cooley AC, Garcia E, Scholl LM, Lindeman NI, **Wagle N**, Garraway L, Cibulskis K, Carter SL, Lawrence M, Getz G, Meyerson ML, Hahn WC, and MacConaill LE. Targeted sequencing to detect somatic mutations, translocations and copy-number variation in human tumors simultaneously. 104th American Association for Cancer Research Annual Meeting, Washington, DC, April 6-10, 2013.
5. Rodon J, Juric D, Gonzalez-Angulo A, Bendell J, Berlin J, Bootle D, Gravelin K, Huang A, Derti A, Lehar J, Würthner J, Boehm M, van Allen E, **Wagle N**, Garraway LA, Yelensky R, Stephens PJ, Miller VA, Schlegel R, Quadt C, Baselga J. Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. 104th American Association for Cancer Research Annual Meeting, Washington, DC, April 6-10, 2013. [Oral Abstract]
6. Lorch JH, Busaidy N, Ruan DT, Janne PA, Limaye SA, Wirth LJ, Barletta JA, Rabinowits G, Garraway LA, Van Allen EM, **Wagle N**, Hanna GJ, Misiukiewicz K, Suda M, Haddad TC, Devine CE, Williams A, Warsi G, Posner MR, and Haddad RI. A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). 2013 ASCO Annual Meeting, Chicago, IL, May 31- June 4, 2013. [Poster Discussion]
7. **Wagle N**, MacConaill LE, Garcia E, Kuo FC, Longtine JA, Garber JE, Janeway KA, Fuchs CS, Bertagnolli MM, Soiffer R, Matulonis U, Lin NU, Hahn WC, Garraway LA, Kantoff PW, Lindeman NI, and Rollins BJ. PROFILE: Broadly based genomic testing for all patients at a major cancer center. 2013 ASCO Annual Meeting, Chicago, IL, May 31- June 4, 2013. [Poster Discussion]
8. Van Allen EM*, **Wagle N***, Carter SL, Sucker A, Farlow D, Hodis E, Taylor-Weiner A, Berking C, Egberts F, Hassel J, Gogas H, Gutzmer R, Goldinger S, Loquai C, Ugurel S, Zimmer L, Gabriel S, Getz G, Garraway LA, and Schadendorf D (on behalf of DeCOG). The genetic landscape of clinical resistance to RAF inhibition in melanoma. 2013 ASCO Annual Meeting, Chicago, IL, May 31- June 4, 2013. [Oral Abstract]
(*Dual-First Author)
9. **Wagle N***, Van Allen EM*, Frederick DT, Cooper ZA, Farlow DN, Treacy D, Goetz EM, Johannessen CM, Carter SL, Taylor-Weiner A, Hodis E, Lawrence DP, Sullivan RJ, Getz G, Gabriel SB, Flaherty K, Wargo JA, and Garraway LA. Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. 2013 ASCO Annual Meeting, Chicago, IL, May 31- June 4, 2013. [Poster Discussion]

- b. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.

FORMAL TEACHING OF PEERS

2013	“Genomic Profiling in Breast Cancer” Breast Cancer: New Horizons, Current Controversies Dana-Farber Cancer Institute / Harvard Medical School	Lecture
------	---	---------

LOCAL INVITED PRESENTATIONS

2013	“Tumor Genomic Profiling and Personalized Cancer Medicine” (Part I) DF/HCC Clinical Investigator Course	Lecture
2013	“Tumor Genomic Profiling and Personalized Cancer Medicine” (Part II) DF/HCC Clinical Investigator Course	Lecture
2013	“Implementing Genomics-Driven Cancer Medicine: The Genomics Superhighway Meets the Bikepath of Medical Practice” (with Atul Gawande, MD) Cancer Program Meeting, Broad Institute	Invited Talk
2013	“Clinical and Translational Cancer Genomics” Scientific Speaker Series Genomics Platform, Broad Institute	Invited Talk
2013	“Clinical and Translational Cancer Genomics” Breast Oncology Seminar Series Dana-Farber Cancer Institute	Seminar
2013	“Clinical Cancer Genomics and Precision Cancer Medicine” Radiation Oncology Conference BWH/Dana-Farber Cancer Institute	Seminar
2013	“Clinical Sequencing and Precision Cancer Medicine” Massachusetts General Hospital Cancer Center	Seminar
2013	“Clinical Cancer Genomics and Precision Cancer Medicine” Thoracic Oncology Program Seminar Series Dana-Farber Cancer Institute	Seminar
2013	“Clinical Sequencing and Precision Cancer Medicine” Cancer Program Meeting, Broad Institute	Invited Talk

National

2013	“CanSeq: The Use of Whole Exome Sequencing To Guide the Care of Cancer Patients” 62 nd Meeting of the National Cancer Institute Director’s Consumer Liaison Group (DCLG) National Cancer Institute	Invited Talk
------	---	--------------

	Washington, DC	
2013	“Identification of New Targets and Pathways in Cancer: Translating Basic Discoveries into the Clinic” American Association of Cancer Research Annual Meeting 2013, Washington, DC	Invited Talk & Chairperson
2013	“Genomic and Molecular Profiling: What We Know and What's Coming” Clinical Care in Oncology for the Advanced Practice Provider American Society of Clinical Oncology 2013 Pre-Meeting, Chicago, IL	Invited Talk
2013	“Genomic Testing for All Cancer Patients at Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Boston Children’s Hospital” Next Generation Diagnostics Summit 2013 Washington, DC	Invited Talk
2013	“Clinical and Translational Cancer Genomics” Vanderbilt Ingram Cancer Center Nashville, TN	Invited Talk

International

2013	“Tumor Genomic Profiling: Targeted versus Whole Exome Sequencing” 1 st International Congress on Controversies in Personalized Oncology (CONPO) Barcelona, Spain	Invited Talk
2013	“Clinical and Translational Breast Cancer Genomics” The 3rd Global Cancer Genomics Consortium Symposium: From Oncogenomics to Cancer Care Lisbon, Portugal	Invited Talk
2013	“Clinical Cancer Genomics and Precision Cancer Medicine” Translational Genomics Symposium National Institute of Genomic Medicine (INMEGEN) Mexico City, Mexico	Invited Talk
2013	“Clinical Cancer Genomics and Precision Cancer Medicine” Instituto Nacional de Ciencias Médicas y Nutrición Mexico City, Mexico	Invited Talk

7. INVENTIONS, PATENTS AND LICENSES:

Nothing to report.

8. REPORTABLE OUTCOMES:

Nothing to report.

9. OTHER ACHIEVEMENTS:

a) I became the Co-Chair of the NHGRI Clinical Sequencing Exploratory Research Consortium's Sequencing Standards Working Group, a working group focused on the development of standards for clinical sequencing. The working group consists of members from 9 U.S. institutions conducting clinical sequencing research funded by the NHGRI.

b) I obtained several awards and grants, several of which are related to the preliminary data generated by this award (indicated with an *):

2012 – 2014 *Tumor and Germline Whole Exome Sequencing in Young Women with Breast Cancer*

Susan F. Smith Ctr for Women's Cancers Executive Council: Molecular Signatures of Human Cancers (Wagle)

Principal Investigator (\$144,000)

The overarching goal of this project is to improve our understanding of breast cancer in young women by using cutting-edge genomic technology (massively parallel, or "next-generation" sequencing) to comprehensively characterize all of the known genes (the whole exome) from a collection of tumor and blood samples from 100 women who developed breast cancer before the age of 35.

*2013 – 2015 *Systematic genomic profiling of endocrine-resistant breast cancer*

Landon Foundation-AACR INNOVATOR Award for Research in Personalized Cancer Medicine (Wagle)

Principal Investigator (\$100,000)

The overarching goal of this research is to use comprehensive genomic profiling to test the hypothesis that somatic genetic differences may contribute to endocrine-resistance in breast cancer. Toward this end, a major focus of this grant will leverage massively parallel sequencing technology to characterize the whole exome (the protein coding sequence of the genome) and whole transcriptome (all mRNA transcripts in the cell) of prospectively collected breast cancer samples from women with acquired resistance to hormonal therapies.

2013 – 2018 *Overcoming Resistance to HER2-Directed Therapies for Breast Cancer, Dana-Farber/Harvard SPORE in Breast Cancer (Project 2)*

The National Cancer Institute / National Institutes of Health 1P50CA168504-01A1 (Winer)

Co-Investigator

This project uses state-of-the-art genetically engineered mouse models and a cutting edge clinical trial to evaluate resistance mechanisms in HER2+ breast cancer. It seeks to overcome this resistance by further interrogating the PI3 kinase pathway, and will evaluate sensitivity and resistance to PI3 kinase inhibitors.

2013 – 2018 *Tissue and Pathology Core, Dana-Farber/Harvard SPORE in Breast Cancer (Core D)*

The National Cancer Institute / National Institutes of Health 1P50CA168504-01A1 (Winer)

Co-Director

The Tissue and Pathology Core will maintain tissue/blood repositories for the SPORE Projects.

This Core will also provide pathology services that are critical to many of the translational research aims in the Projects.

2014 – 2015 *Exceptional Responses in Cancer*

Next Generation Fund of the Broad Institute of Harvard and MIT (Wagle)

Principal Investigator (\$100,000)

This project uses deep molecular characterization, including whole exome and whole transcriptome sequencing, of tumors from patients who have had exceptional responses – exquisite sensitivity or unexpectedly durable responses to treatment – in order to better understand predictors of response and to develop novel strategies for treating cancer.

*2014 – 2016 *Identifying resistance mechanisms in ER+ breast cancer by translational genomics*

Dana-Farber/Harvard SPORE in Breast Cancer Career Development Award (Wagle)

Principal Investigator (\$80,000)

The goal of this research is to apply both genomic characterization and systematic functional approaches to test the hypothesis that somatic genetic differences may contribute to endocrine-resistance in breast cancer. To accomplish this, we will employ complementary genomic and *in vitro* experimental approaches that address two critical challenges facing clinicians who treat ER+ breast cancer: identifying determinants of resistance to endocrine therapy, and elucidating the spectrum of clinically relevant alterations and actionable dependencies in patients with endocrine-resistant breast cancer.

10. TRAINING AND PROFESSIONAL DEVELOPMENT:

My training has been enhanced by a number of ongoing weekly meetings and working groups that focus on areas in which I seek to continue my development. These include weekly laboratory meetings, a Cancer Resistance working group (monthly), a Cancer Genome Working group (weekly), a weekly Cancer Program Meeting, the Breast Oncology tumor board (weekly) and the Breast Oncology weekly seminar series, as well as a number of other periodic conferences and seminar series. I have had the opportunity to attend these seminars and courses as well as present my work in them. In addition, I have had the opportunity to attend numerous scientific meetings over the past year, including the San Antonio Breast Cancer Symposium, the AACR Annual Meeting, the ASCO Annual Meeting, the AACR-EORTC-NCI Meeting on Molecular Targets and Cancer Therapeutics, and several meetings and workshops of the NHGRI Clinical Sequencing Exploratory Research Consortium.

11. REFERENCES:

1. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerød A; Oslo Breast Cancer Consortium (OSBREAC), Lee MT, Shen CY, Tee BT, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van 't Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SA, Salomon AV, Børresen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, Stratton MR. The landscape of cancer genes and mutational processes in breast cancer. *Nature*. 2012 May

16;486(7403):400-4. doi: 10.1038/nature11017. PubMed PMID: 22722201; PubMed Central PMCID: PMC3428862.

2. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhir R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M. Sequence analysis of mutations and translocations across breast cancer subtypes. *Nature*. 2012 Jun 20;486(7403):405-9. doi: 10.1038/nature11154. PubMed PMID: 22722202.
3. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. *Nature*. 2012 Apr 4;486(7403):395-9. doi: 10.1038/nature10933. PubMed PMID: 22495314.
4. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23. PubMed PMID: 23000897; PubMed Central PMCID: PMC3465532
5. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Alred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER. Whole-genome analysis informs breast cancer response to aromatase inhibition. *Nature*. 2012 Jun 10;486(7403):353-60. doi: 10.1038/nature11143. PubMed PMID: 22722193; PubMed Central PMCID: PMC3383766.
6. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Lee RS, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature*. 2013 Jul 11;499(7457):214-8. doi: 10.1038/nature12213. Epub 2013 Jun 16. PubMed PMID: 23770567.
7. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature*. 2014 Jan 23;505(7484):495-501. doi: 10.1038/nature12912. Epub 2014 Jan 5. PubMed PMID: 24390350.